Rasagiline (Azilect®, Lundbeck), an irreversible monoamine oxidase-B (MAO-B) inhibitor for the treatment of Parkinson’s disease (PD), has been available in Europe and the United States for around a decade. With the approval of rasagiline in Singapore, Professor Fabrizio Stocchi presented the pivotal clinical trials of the drug and its role in the overall management of PD.
Fabrizio Stocchi, MD, PhD, is Professor of Neurology, Consultant in Neurology and Director of the Parkinson's disease and Movement disorders research centre and director of the drug development research centre at the University and Institute for Research and Medical Care IRCCS San Raffaele Rome. He is also Scientific advisor of the Institute for Parkinson's Disease Research in Vicenza. Professor Stocchi was awarded his MD from the University of L'Aquila and his PhD from the University of Catania.
Professor Stocchi’s research activities have centred on neuropharmacology in the field of movement disorders and neurodegenerative diseases. Professor Stocchi pioneered (along with Dr. Obeso and Tom Chase) in the 80's the concept of "continuous dopaminergic stimulation" for Parkinson’s disease and started the subcutaneous and intraintestinal infusion of dopaminergic drugs. He has published many books and papers on the genetics, clinical diagnosis, characterisation and treatment of Parkinson's disease, as well as in preclinical research into the disease. He is an active member of 11 societies, including the Movement Disorders Society, the WFN society where is member of the extrapiramidal committee, the European Clinical Neuropharmacology Society and the European Federation Neurological Society.